These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study. Bourque PR; Pringle CE; Cameron W; Cowan J; Chardon JW PLoS One; 2016; 11(8):e0159993. PubMed ID: 27490101 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R; Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163 [TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation. Eienbröker C; Seitz F; Spengler A; Kurz H; Seipelt M; Sommer N; Oertel WH; Timmesfeld N; Tackenberg B Muscle Nerve; 2014 Dec; 50(6):999-1004. PubMed ID: 24710856 [TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R; Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511 [TBL] [Abstract][Full Text] [Related]
7. Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial. Beecher G; Anderson D; Siddiqi ZA Neurology; 2017 Sep; 89(11):1135-1141. PubMed ID: 28814461 [TBL] [Abstract][Full Text] [Related]
8. Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis. Yasuda M; Uzawa A; Ozawa Y; Kojima Y; Onishi Y; Akamine H; Kuwabara S Scand J Immunol; 2022 Feb; 95(2):e13122. PubMed ID: 34796975 [TBL] [Abstract][Full Text] [Related]
9. A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations. Karelis G; Balasa R; De Bleecker JL; Stuchevskaya T; Villa A; Van Damme P; Lagrange E; Heckmann JM; Nicolle M; Vilciu C; Bril V; Mondou E; Griffin R; Chen J; Henriquez W; Garcia B; Camprubi S; Ayguasanosa J Eur Neurol; 2019; 81(5-6):223-230. PubMed ID: 31655810 [TBL] [Abstract][Full Text] [Related]
10. An update on the use of immunoglobulins as treatment for myasthenia gravis. Alcantara M; Barnett C; Katzberg H; Bril V Expert Rev Clin Immunol; 2022 Jul; 18(7):703-715. PubMed ID: 35639497 [TBL] [Abstract][Full Text] [Related]
11. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Liu JF; Wang WX; Xue J; Zhao CB; You HZ; Lu JH; Gu Y Ther Apher Dial; 2010 Apr; 14(2):153-60. PubMed ID: 20438536 [TBL] [Abstract][Full Text] [Related]
12. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison. van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198 [TBL] [Abstract][Full Text] [Related]
13. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM; Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245 [TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. Meisel A; Annane D; Vu T; Mantegazza R; Katsuno M; Aguzzi R; Frick G; Gault L; Howard JF; J Neurol; 2023 Aug; 270(8):3862-3875. PubMed ID: 37103755 [TBL] [Abstract][Full Text] [Related]
19. A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis. Yin J; Zhao M; Xu X; Zhang M; Xu Z; Li Z; Qin X; Li Z; Zhao C; Zhou H; Ma Y; Cao W; Wang G; Lin Y; Zhang J; Zhang X; Cai H; Qian W; Wang Y; Zhang X; Liu G; Wang J; Qiu W; Min L; Li J; Deng H; Chu L; Zhang Y; Fang J Eur J Neurol; 2024 Aug; 31(8):e16322. PubMed ID: 38726639 [TBL] [Abstract][Full Text] [Related]